RTP Mobile Logo
CNS Cancer Update, Issue 2, 2011
Released December 2011

Featuring interviews with Drs Marc Chamberlain and Timothy F Cloughesy. (Audio Content)

CE Disclosures and Faculty Information


    Brain tumors are a diverse group of neoplasms arising from different cells within the central nervous system (CNS) or from systemic tumors that have metastasized to the CNS. Primary brain tumors include a number of histologic types with markedly different tumor growth rates and are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma) and glioblastoma multiforme (GBM) based on their histopathologic features. Despite treatment, the median survival for anaplastic oligodendroglioma is 2 to 3 years, and patients with GBM can succumb to their disease within a year of the onset. Thus, clinical education regarding standard and evolving best-practice therapeutic management of these neoplasms is essential to improving patient outcomes. To bridge the gap between research and patient care, this issue of CNS Cancer Update features one-on-one discussions with leading neurooncologists and neurosurgeons. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists with the formulation of state-of-the-art clinical management strategies, which in turn facilitates optimal patient care.

    • Utilize case-based learning to facilitate the development of evidence-based and individualized management strategies for newly diagnosed and recurrent primary CNS cancer.
    • Identify strategies to distinguish between true disease progression and radiographic pseudoprogression in patients with malignant glioma who have undergone chemoradiation therapy.
    • Evaluate the prognostic and/or predictive role of molecular profiling (eg, MGMT methylation status) in primary CNS cancers.
    • Develop evidence-based clinical management strategies for recurrent or progressive GBM, including the use of anti-angiogenic therapy.
    • Incorporate key recent clinical trial data into treatment planning for patients with primary CNS lymphomas.
    • Anticipate future protocol and nonprotocol treatment options for patients based on investigational strategies using novel targets, agents and biomarkers in CNS cancers.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr ChamberlainAdvisory Committee: Genentech BioOncology, Lilly USA LLC, Mundipharma International Limited, Sigma-Tau Pharmaceuticals Inc; Paid Research: Exelixis Inc, MedImmune Inc, Myrexis Inc; Speakers Bureau: Genentech BioOncology, Schering-Plough Corporation, Sigma-Tau Pharmaceuticals Inc. Dr CloughesyAdvisory Committee: Amgen Inc, Genentech BioOncology, Lilly USA LLC, Novartis Pharmaceuticals Corporation; Consulting Agreement: Roche Laboratories Inc; Speakers Bureau: Schering-Plough Corporation.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genentech BioOncology.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2011
    Expiration date: December 2012

Acknowledge and close

Listen to audio:
CNS Cancer Update, Issue 2, 2011
Released December 2011

Featuring interviews with Drs Marc Chamberlain and Timothy F Cloughesy. (Audio Content)

Read print: